We’re advancing antibodies for obesity and cardiometabolic disease

Human genetic studies indicate that loss-of-function variants in INHBE (encoding Activin E) are associated with reduced visceral adiposity and improved lipid profiles. IBIO-610 is a monoclonal antibody designed to block Activin E and engineered for extended half-life, with the goal of enabling infrequent dosing (e.g., 2–4 times per year) for obesity and cardiometabolic indications.

We are developing a bispecific antibody designed to inhibit myostatin and activin A signaling to preserve lean mass and improve the quality of weight loss (favoring fat loss with minimal loss of lean tissue), including as a potential adjunct to currently approved GLP-1–based therapies. In addition, emerging clinical evidence suggests that blockade of the activin and myostatin pathways may have relevance in pulmonary hypertension associated with HFpEF.

Myostatin is a natural brake on skeletal muscle growth. IBIO-600 is a long-acting, half-life-extended monoclonal antibody blocking myostatin signaling to support lean mass preservation and improved body composition in obesity, including potential use alongside currently approved GLP-1–based therapies. The molecule is engineered for infrequent dosing (e.g., 2–4 times per year), and the myostatin pathway also provides optionality for future exploration in neuromuscular diseases such as spinal muscular atrophy (SMA).

Amylin is a pancreatic hormone that promotes satiety and appetite control through activation of the amylin receptor. While existing approaches rely on once-per-week peptide agonists, we are exploring a novel antibody-based strategy designed to engage the amylin receptor with long-acting, more controlled pharmacology. This approach has the potential to offer improved tolerability, infrequent dosing, and a mechanistically complementary alternative to currently approved GLP-1 therapies for weight management.